Leaute-Labreze C, Prey S, Ezzedine K. Infantile haemangioma: part II. Risks, complications and treatment[J]. J Eur Acad Dermatol Venereol, 2011, 25(11): 1254-1260.
[2]
Leaute-Labreze C, de la Roque ED, Hubiche T, et al. Propranolol for severe hemangiomas of infancy[J]. N Engl J Med, 2008, 358(24): 2649-2651.
[3]
de Melo JN, Rotter A, Rivitti-Machado MC, et al. Propranolol for treatment of infantile hemangiomas[J]. An Bras Dermatol, 2013, 88(6 Suppl 1): 220-223.
[4]
Albuquerque JC, Magalhães RA, Félix JA, et al. Treatment of children and adolescents with hemangioma using propranolol: preliminary results from a retrospective study[J]. Sao Paulo Med J, 2014, 132(1): 48-54.
[5]
Andersen IG, Rechnitzer C, Charabi B. Effectiveness of propranolol for treatment of infantile haemangioma[J]. Dan Med J, 2014, 61(2): A4776.
[6]
Schiestl C, Neuhaus K, Zoller S, et al. Efficacy and safety of propranolol as first-line treatment for infantile hemangiomas[J]. Europ J Pediatr, 2011, 170(4): 493-450.
[7]
de Graaf M, Breur JM, Raphaël MF, et al. Adverse effects of propranolol when used in the treatment of hemangiomas: a case series of 28 infants[J]. J Am Acad Dermatol, 2011, 65(2): 320- 327.
[8]
Szychta P, Stewart K, Anderson W. Treatment of infantile haemangiomas with propranolol: clinical guidelines[J]. Plastic Reconstr Surg, 2014, 133(4): 852-862.
Garzon MC, Lucky AW, Hawrot A, et al. Ultrapotent topical corticosteroid treatment of hemangiomas of infancy[J]. J Am Acad Dermatol, 2005, 52(2): 281-286.
[12]
Leaute-Labreze C, Prey S, Ezzedine K. Infantile haemangioma: part I. Pathophysiology, epidemiology, clinical features, life cycle and associated structural abnormalities[J]. J Eur Acad Dermatol Venereol, 2011, 25(11): 1245-1253.
